Pfizer Inc
Inside the deal: Roche and Zealand Pharma’s $5.3 billion obesity drug gambit
A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” […]
Read More
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
Check out the companies making headlines in midday trading: Spotify — Shares of the music streaming company lost 3.8% on the back of disappointing results. Spotify reported first-quarter operating income of 509 million euros, while analysts polled by FactSet expected 519.9 million euros. Spotify’s revenue of 4.2 billion euros was in line with estimates, while […]
Read More
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and […]
Read More
Stocks making the biggest moves premarket: Spotify, Coca-Cola, Sherwin-Williams, UPS and more
Check out the companies making headlines in premarket trading. Spotify — The music streaming stock tumbled 5% after reporting first-quarter operating income of 509 million euros, while analysts polled by FactSet had penciled in 519.9 million euros. Spotify’s 4.2 billion euro revenue was in line with estimates, while its monthly active users of 678 million […]
Read More
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
The Pfizer logo is seen outside the pharmaceutical company’s manufacturing plant, in Newbridge, Ireland February 10, 2025. Clodagh Kilcoyne | Reuters Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company’s sales fell, largely due to dwindling revenue for its antiviral Covid pill Paxlovid. The company previously […]
Read More
Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise
Bristol Myers Squibb ‘s earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now. Revenue in the first quarter, which ended March 31, dipped 6% to $11.2 billion but topped estimates of $10.7 billion, according to LSEG. Adjusted earnings per share of $1.80 beat expectations […]
Read More
Corporate America shelled out millions for Trump’s inauguration. Now he’s upending many of their businesses
U.S. President Donald Trump delivers remarks at the Business Roundtable’s quarterly meeting at the Business Roundtable headquarters on March 11, 2025 in Washington, DC. Andrew Harnik | Getty Images America’s richest and most powerful companies shelled out millions to fund President Donald Trump’s inauguration festivities. Three months later, some may be asking whether the famously […]
Read More
Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma
U.S. President Donald Trump speaks to the media during the annual White House Easter Egg Roll, on the South Lawn of the White House in Washington, D.C., U.S., April 21, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to […]
Read More
Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs. The news Club name Lilly said its daily obesity pill was successful in a late-stage trial for Type 2 diabetes — sending shares soaring more […]
Read More
CNBC Daily Open: Consumers are worried over the economy. The White House insists it’ll be fine
People shop at a grocery store in Manhattan on April 01, 2025, in New York City. Spencer Platt | Getty Images A day without major tariff developments from U.S. President Donald Trump’s administration is, for markets, a day of cautious optimism (or at least what passes as “optimism” in such unusual times). There was breathing […]
Read More